Celgene has recruited an R&D executive as part of an organisational shake-up designed to tackle issues with its drug pipeline. Alise Reicin, MD, who worked with Merck on immuno-oncology drug Keytruda, has been brought in to lead mid- to late-stage drug development across Celgene’s portfolio. The company is also looking at ways to improve the way it manages clinical trials and how it integrates data from different studies.
Celgene has recruited an R&D executive as part of an organisational shake-up designed to tackle issues with its drug pipeline. Alise Reicin, MD, who worked with Merck on immuno-oncology drug Keytruda, has been brought in to lead mid- to late-stage drug development across Celgene’s portfolio. The appointment follows an audit in May which revealed that two-thirds of the firm’s R&D programmes had failed over the past five years, with only one in 20 programmes resulting in a marketed product.